Swiss National Bank boosted its holdings in shares of Qiagen NV (NASDAQ:QGEN) by 7.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,034,966 shares of the company’s stock after purchasing an additional 68,260 shares during the quarter. Swiss National Bank owned approximately 0.45% of Qiagen worth $33,476,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of QGEN. Wells Fargo & Company MN increased its holdings in shares of Qiagen by 44.1% in the 4th quarter. Wells Fargo & Company MN now owns 124,743 shares of the company’s stock valued at $3,859,000 after acquiring an additional 38,149 shares during the last quarter. Citadel Advisors LLC boosted its position in Qiagen by 816.3% during the 4th quarter. Citadel Advisors LLC now owns 1,051,713 shares of the company’s stock valued at $32,529,000 after purchasing an additional 936,936 shares during the period. Vident Investment Advisory LLC boosted its position in Qiagen by 54.1% during the 4th quarter. Vident Investment Advisory LLC now owns 593,498 shares of the company’s stock valued at $18,357,000 after purchasing an additional 208,430 shares during the period. Two Sigma Investments LP boosted its position in Qiagen by 0.9% during the 4th quarter. Two Sigma Investments LP now owns 594,920 shares of the company’s stock valued at $18,401,000 after purchasing an additional 5,107 shares during the period. Finally, Geode Capital Management LLC boosted its position in Qiagen by 14.0% during the 4th quarter. Geode Capital Management LLC now owns 669,560 shares of the company’s stock valued at $20,709,000 after purchasing an additional 82,026 shares during the period. Institutional investors own 62.23% of the company’s stock.
Shares of Qiagen opened at $35.09 on Friday, Marketbeat reports. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. Qiagen NV has a fifty-two week low of $34.89 and a fifty-two week high of $35.09.
Qiagen announced that its Board of Directors has authorized a stock buyback plan on Wednesday, January 31st that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
A number of research firms recently issued reports on QGEN. Goldman Sachs restated a “buy” rating on shares of Qiagen in a research report on Wednesday. Commerzbank restated a “buy” rating on shares of Qiagen in a research report on Wednesday, May 9th. Citigroup boosted their price objective on Qiagen from $31.00 to $35.00 and gave the company a “neutral” rating in a research report on Friday, May 4th. BidaskClub upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Wednesday, February 21st. Finally, JPMorgan Chase restated a “neutral” rating on shares of Qiagen in a research report on Thursday, May 3rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. Qiagen currently has a consensus rating of “Hold” and a consensus price target of $35.55.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.